biologic

Bexsero

Meningococcal Group B Vaccine

Loss of exclusivityJanuary 2027projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameBexsero
Active ingredientMeningococcal Group B Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bexsero patent cliff — loss of exclusivity January 2027 | CliffBio